- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03925207
Retrobulbar Block and/or General Anesthesia for Orbital Ball Implants After Enucleation Surgery. (pprb)
December 16, 2020 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
Retrobulbar Block and/or General Anesthesia for Orbital Ball Implants After Enucleation Surgery.: a Retrospective Observational Study
Retrobulbar block is used to provide perioperative analgesia and anesthesia for orbital ball implants after enucleation surgery in the investigator's hospital.
Retrobulbar block alone can provide quicker recovery, decreased time to discharge, opioid sparing, reduced costs.
However, patients undergoing orbital ball implants after enucleation surgery with retrobulbar block alone suffered more preoperative and intraoperative anxiety,postoperative pain, and postoperative nausea and vomiting.
General anesthesia alone is administered to patients undergoing orbital ball implants after enucleation surgery and opioids are used in adjunct with general anesthesia to suppress pain and hemodynamic stress associated with surgical trauma.
GA only associated with more systemic opioids, short-term cognitive impairment, somnolence, and postoperative nausea and vomiting that can increase patient morbidity and delay discharge.
Opioids, however, can result in adverse effects such as nausea and vomiting, pruritus, sedation.
As a result of this growing demand of efficient and effective anesthesia management for orbital ball implants after enucleation surgery is becoming increasingly important.
Numerous studies have reported benefits of an retrobulbar block for orbital ball implants after enucleation surgery, including quicker recovery and decreased time to discharge, decreased pain scores, opioid sparing, reduced costs, less intraoperative hemodynamic variability, improved patient satisfaction, and, in some cases, reduced GA- and/or opioid-related side effects.
A recent systematic review examining all modes of postoperative pain management following orbital ball implants after enucleation surgery concluded that retrobulbar block are superior to all other forms of postoperative pain control.
Study Overview
Status
Completed
Conditions
Detailed Description
This retrospective review examined postoperative outcomes for orbital ball implants after enucleation surgery patients who underwent surgery with general anesthesia (GA), single-shot retrobulbar block, or retrobulbar block combined with GA.
The primary outcome included postoperative pain upon arrival at and discharge from the PACU, analgesic consumption and rescue analgesia.
Secondary outcomes was time to discharge from the postanesthesia care unit (PACU) as well as GA and opioid-related side effects and retrobulbar block- associated neurological complications.
The investigators speculated that patients who received an retrobulbar block before GA had less postoperative pain, and reduced analgesic requirements when compared with patients who received GA Only or retrobulbar block alone.
Study Type
Observational
Enrollment (Actual)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hangzhou, China
- 叶伟娣
-
Hanzhou, China
- Weidi Ye
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients were included if they underwent orbital ball implants after enucleation surgery by one ophthalmologist surgeon specializing in oculoplastic and orbital surgery at our centre above 18 years old
Description
Inclusion Criteria:
- Patients were included if they underwent orbital ball implants after enucleation surgery by one ophthalmologist surgeon specializing in oculoplastic and orbital surgery at our centre.
Exclusion Criteria:
- Patients were excluded if they underwent other concurrent surgical procedures, or were under 18 yr of age.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative pain upon arrival at and discharge from the postanesthesia care unit
Time Frame: through study completion: an average of 24 hour
|
Visual Analogue Scale score(0-10, no pain - worse) of postoperative pain,
|
through study completion: an average of 24 hour
|
|
analgesic consumption
Time Frame: through study completion: an average of 24 hours
|
Dose of analgesic consumption
|
through study completion: an average of 24 hours
|
|
rescue analgesia
Time Frame: through study completion, an average of 24 hours
|
Rate of rescue analgesia
|
through study completion, an average of 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative nausea and vomiting
Time Frame: through study completion, an average of 24 hours
|
Rate of postoperative nausea and vomiting
|
through study completion, an average of 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Zhiying Wu, Doctor, Second Affiliated Hospital, School of Medicine, Zhejiang University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2019
Primary Completion (Actual)
December 28, 2019
Study Completion (Actual)
July 18, 2020
Study Registration Dates
First Submitted
February 26, 2019
First Submitted That Met QC Criteria
April 21, 2019
First Posted (Actual)
April 24, 2019
Study Record Updates
Last Update Posted (Actual)
December 19, 2020
Last Update Submitted That Met QC Criteria
December 16, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2019-2-18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.